AZ-AXWAY
1.7.2024 18:43:32 CEST | Business Wire | Press release
Axway (Euronext: AXW.PA), a leading provider of API management and integration software, is proud to announce that it has been positioned as a Leader in The Forrester Wave™: API Management Software, Q3 2024, published on July 1, 2024.¹
"We are always honored when our customers share the positive experiences and outcomes they have had with Axway," said Vince Padua, Chief Product Officer at Axway. "We're invested in their success, providing the expertise and guidance needed to treat APIs as strategic business products.”
Axway was one of 15 select companies that Forrester invited to participate in its evaluation, The Forrester Wave™: API Management Software, Q3 2024. In this evaluation of its Amplify API Management, Axway earned the highest scores possible in seven evaluation criteria, including federated gateway management, API product management, and adoption.
“This recognition validates for us our unique API business strategy program, which is just one example of how we go above and beyond to ensure you extract maximum value from API investments. We empower organizations with universal API management tools that break down barriers and provide a single source of truth for the entire API landscape,” said Padua.
The report notes: “Axway focuses on digital business that is multicloud, multiprotocol, and multigateway. Its roadmap seeks to deliver a more unified product line, non-REST protocol enhancements, more gateway federation, AI for API creation and consumption, and gateway modernization... It is the only vendor in this evaluation to provide robust support for third-party federated gateways...” ¹
“The Amplify platform lets you discover, use, and govern APIs across multiple gateways, vendors, and environments, simplifying adoption and use of APIs. But providing an industry-leading API management solution isn’t enough,” adds Padua. “Just as essential is accompanying our customers in designing an API management strategy that will drive the best results from a company’s investment.”
According to the report, “Reference customers say Axway is a supportive partner that listens to its customers. They also love its support for third-party gateways.” ¹
With Amplify API Management, the global manufacturing and engineering innovator Bosch was able to accelerate product and service innovation.
“We manage over 2,000 APIs using Amplify API Management, with a volume of several hundred million transactions per month. These APIs enable a wide range of use cases, from connecting SAP S/4HANA with other line-of-business solutions to supporting smart heating systems for office buildings,” said David Geiger, Head of API Management at Bosch Digital.
“And with Amplify Marketplace, developers can easily find the right APIs without traversing the entire organization; this saves a huge amount of time.”
Baird, an investment bank and financial services company, drove rapid adoption with a central API catalog and secure self-service consumption with Axway.
“Today, our developers can see all the APIs their peers have developed, identify any application dependences, and check the source repository to see who last worked on it,” said Jim Cornelius, SVP, IT Architect at Baird. “With a central view of which APIs are available, our teams can leverage already-existing code or even an entire API created by another team to accelerate their own development work. Without a doubt, this capability is reducing duplication of effort in our development process — helping us to minimize our time to market for new data-driven services.”
Click here to view a complimentary copy of The Forrester Wave™ report.
¹ The Forrester Wave™: API Management Software, Q3 2024, Forrester Research, Inc., July 1, 2024
About Axway
Axway is an independent technology provider that sustainably grows enduring value for our customers based on a history of trust, security, and stability that goes back nearly 25 years. Our extensive portfolio, which encompasses Managed File Transfer, B2B Integration, Financial Accounting Hub, and comprehensive API management through Amplify, empowers organizations to seamlessly integrate their internal and external ecosystems and succeed in a shifting digital business landscape. Learn more at axway.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240701226257/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CorFlow Therapeutics Announces Successful Completion of Phase 1 and First Patients Enrolled in Phase 2 of the MOCA II Pivotal Trial, Approval to Start the REVITALISE RCT in Europe, and Strengthening of Clinical Leadership30.4.2026 13:00:00 CEST | Press release
Milestones advance clinical progress and path to commercialization CorFlow Therapeutics AG (CorFlow), a clinical-stage company focused on transforming the diagnosis and treatment for heart attack patients, today announced multiple milestones in advancing its clinical program and the strengthening of clinical leadership. Phase 1 of the company’s MOCA II FDA Pivotal Trial was successfully reached after safety and performance goals were met with STEMI heart attack patients who had the proprietary PCoFI diagnostic measurement of microvascular obstruction (MVO) made during a stenting procedure, when compared to the reference standard diagnosis by cardiac MRI in the subsequent days. Phase 1 included 19 patients enrolled across 5 US and 3 European sites. MOCA II follows the FIH MOCA I study and primarily aims to validate the threshold value of the proprietary PCoFI measurement for diagnosing MVO in the setting of primary angioplasty compared to cardiac MRI. This milestone achievement, which w
Agendia to Present New Data Demonstrating the Expanded Clinical Utility of MammaPrint® and BluePrint® at the 2026 ESMO Breast Cancer Annual Congress30.4.2026 13:00:00 CEST | Press release
Poster presentations highlight the prognostic value of MammaPrint + Blueprint in small, node-negative tumors and impact of BMI on recurrence dynamics Agendia®, Inc., a leader in precision oncology for breast cancer, today announced it will present new data at the 2026 European Society for Medical Oncology (ESMO) Annual Congress on Breast Cancer, taking place May 6-8 in Berlin, Germany. The company will present two posters featuring data from the prospective FLEX Study and an independent post hoc analysis of the landmark MINDACT trial that underscore the prognostic value of MammaPrint® + BluePrint® in early-stage breast cancer (EBC). Poster #65P | Thursday, May 7, 13:15 – 14:15 p.m. CEST | Presenter: Elena Shagisultanova Prognostic Performance of MammaPrint in Patients with Small T1a, b, and c Node-Negative Early Breast Cancer A retrospective analysis from the FLEX Study involving 4,349 patients highlights the biological heterogeneity within small, node-negative (T1a, b, and c) tumors –
The Biggest Predictor of Business Growth Is Behavior30.4.2026 09:00:00 CEST | Press release
New IDEO research reveals a gap in the behaviors that most drive growth: long-term vision, rapid experimentation, and team autonomy—with only 10% of leaders saying their company excels at the combination. IDEO, the global design and innovation company, today announced the IDEO Innovation Quotient (IDEO IQ), a new report measuring how workplace behaviors drive business performance across 100 of the world’s largest companies. Those with the highest IDEO IQ scores earned nearly $20 billion in profit last year—50% higher than average and three times more than those ranked at the bottom. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429978890/en/ The IDEO Innovation Quotient (IDEO IQ) is a new report measuring how workplace behaviors drive business performance across 100 of the world’s largest companies. The IDEO IQ surveyed 266 leaders in product and innovation roles at 100 of the world’s largest companies across the Media &
Suzano Sells 12.7 Million Tonnes of Pulp for the First Time in Its History30.4.2026 00:22:00 CEST | Press release
Suzano(B3: SUZB3 | NYSE: SUZ), the world’s largest pulp producer, announces its results for the first quarter of 2026 (1Q26), achieving a new all‑time record in pulp sales. Over the 12‑month period from April 2025 to March 2026, the company sold 12.7 million tonnes of pulp, the highest volume ever recorded in its history. During the same period, Suzano also sold 1.7 million tonnes of paper across the packaging, printing and writing, specialty, and tissue segments. This unprecedented sales level mainly reflects the increase in production capacity following the start‑up of the Ribas do Rio Pardo pulp mill in the state of Mato Grosso do Sul, as well as Suzano’s strong operational efficiency across its production lines and supply chains, serving customers in more than 100 countries worldwide. In the first quarter of 2026, Suzano sold a total of 3.2 million tonnes, comprising 2.8 million tonnes of pulp and 378 thousand tonnes of paper. Net revenue amounted to BRL 11.0 billion, while adjuste
The Estée Lauder Companies Announces Minority Investment in Luxury Clinical Skin Care Brand 111SKIN29.4.2026 22:30:00 CEST | Press release
Surgeon-Founded Brand Anchored by Innovative NAC Y2™ Technology The Estée Lauder Companies Inc. (NYSE:EL) today announced a minority investment in 111SKIN, a luxury clinical skin care brand founded by renowned plastic and reconstructive surgeon Dr. Yannis Alexandrides. Terms of the investment were not disclosed. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429495879/en/ 111SKIN's Reparative Collection Founded in 2012, 111SKIN was originally developed by Dr. Alexandrides to accelerate his patients’ healing time following procedures. At the heart of the brand is its innovative NAC Y2™, a pioneering complex designed to support skin repair and maintain a healthy, radiant and resilient complexion. Building on the foundation of this clinical expertise, 111SKIN has developed a portfolio of more than 30 products, anchored by its Black Diamond and Reparative collections and priced from $50 to $1,000. “Skin care is entering a new
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom